Literature DB >> 9345169

Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study.

P A Wylie1, D Stevens, W Drake, J Stuart, K Cartwright.   

Abstract

OBJECTIVE: To study changes in the epidemiology and management of meningococcal disease in one health district during a period of high local incidence of disease.
DESIGN: Prospective case ascertainment and data collection over 14 years, with retrospective analysis of cases.
SETTING: West Gloucestershire (population 320,000).
SUBJECTS: Residents developing meningococcal disease between 1 January 1982 and 31 December 1995.
RESULTS: 252 cases of invasive meningococcal disease were identified, of which 102 (40%) were officially notified and 191 (76%) were confirmed by culture from a deep site. The observed disease incidence of 5.6/100,000/year was about 2.7 times the national incidence (as measured by either statutory notifications or reference laboratory reports). The period 1983-90 was characterised by a prolonged localised outbreak due to serogroup B serotype 15 sulphonamide resistant (B15R) strains. General practitioners gave benzylpenicillin before hospital admission to 18% of patients who presented with meningococcal disease in the first half of the study period and to 40% who presented in the second half. The overall case fatality rate was 6.7% (17/252). Four deaths were directly or indirectly related to lumbar puncture. Of 120 patients whose lumbar puncture yielded meningococci, nine (8%) showed no abnormality on initial examination.
CONCLUSIONS: Neither laboratory records nor formal notifications alone can give an accurate estimate of the incidence of meningococcal disease. Because of the dangers of lumbar puncture, the frequency of misleading negative initial findings, and the advent of new diagnostic techniques, the need for samples of cerebrospinal fluid should be critically questioned in each case of suspected meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345169      PMCID: PMC2127533          DOI: 10.1136/bmj.315.7111.774

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  21 in total

1.  The role of lumbar puncture in suspected CNS infection--a disappearing skill?

Authors:  R Kneen; T Solomon; R Appleton
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

Review 2.  When to do a lumbar puncture.

Authors:  F A I Riordan; A J Cant
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

Review 3.  Lumbar puncture following febrile convulsion.

Authors:  W Carroll; D Brookfield
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

Review 4.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

5.  Case fatality rates for meningococcal disease in an English population, 1963-98: database study.

Authors:  Michael J Goldacre; Stephen E Roberts; David Yeates
Journal:  BMJ       Date:  2003-09-13

6.  Meningitis is a common cause of convulsive status epilepticus with fever.

Authors:  R F M Chin; B G R Neville; R C Scott
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

7.  Mortality in severe meningococcal disease.

Authors:  K Thorburn; P Baines; A Thomson; C A Hart
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

Review 8.  Pre-admission antibiotics for suspected cases of meningococcal disease.

Authors:  Thambu D Sudarsanam; Priscilla Rupali; Prathap Tharyan; Ooriapadickal Cherian Abraham; Kurien Thomas
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

9.  Clinical management of meningococcal disease. Coning may occur without lumbar puncture being done.

Authors:  T Stephenson
Journal:  BMJ       Date:  1998-03-28

10.  An evidence and consensus based guideline for the management of a child after a seizure.

Authors:  K Armon; T Stephenson; R MacFaul; P Hemingway; U Werneke; S Smith
Journal:  Emerg Med J       Date:  2003-01       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.